HotSpot Therapeutics to Present New Preclinical Data on MALT1 Inhibitor at AACR Malignant Lymphoma Meeting

HotSpot Therapeutics, Inc., a biotechnology company at the forefront of developing oral, small molecule allosteric therapies, announced it will unveil additional preclinical data from its mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program. This announcement will take place at the 4th American Association for Cancer Research (AACR) International Meeting: Advances in Malignant Lymphoma. The meeting is scheduled for June 19-22, 2024, in Philadelphia, Pennsylvania.

The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will occur on Thursday, June 20, 2024, from 5:30 to 7:30 PM Eastern Time at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.

HotSpot Therapeutics specializes in a revolutionary class of allosteric drugs that target specific natural pockets on proteins, known as "natural hotspots." These sites are crucial for regulating a protein's cellular function and are instrumental in drug discovery because they allow for the systematic design of potent and selective small molecules with unique pharmacological properties. The company's proprietary platform, Smart Allostery™, integrates computational methods and AI-driven data analysis of extensive and varied datasets. This approach helps identify natural hotspots, equipping researchers with tailored pharmacological tools and customized chemistry to facilitate the rapid discovery of new hotspot-targeted small molecules.

By leveraging its Smart Allostery™ platform, HotSpot Therapeutics is developing an extensive pipeline of novel allosteric therapies aimed at treating cancer and autoimmune diseases.